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Viruses of the genus Ebolavirus are the causative agents of Ebola virus disease (EVD), of 29 
which there have been only 25 recorded outbreaks since the discovery of Zaire and Sudan 30 
ebolaviruses in the late 1970s.  Until the west African outbreak commencing in late 2013, 31 
EVD was confined to an area of central Africa stretching from the coast of Gabon through 32 
the Congo river basin and eastward to the Great Lakes.  Nevertheless, population serological 33 
studies since 1976, most of which were carried out in the first two decades after that date, 34 
have suggested a wider distribution and more frequent occurrence across tropical Africa.  35 
We review this body of work, discussing the various methods employed over the years and 36 
the degree to which they can currently be regarded as reliable.  We conclude that there is 37 
adequate evidence for a wider geographical range of exposure to Ebolavirus or related 38 
filoviruses and discuss three possibilities that could account for this: a) EVD outbreaks have 39 
been misidentified as other diseases in the past; b) unidentified, and clinically milder, 40 
species of the genus Ebolavirus circulate over a wider range than the most pathogenic 41 
species; c) EVD may be subclinical with a frequency high enough that smaller outbreaks may 42 
be unidentified.  We conclude that the second option is the most likely and therefore 43 
predict the future discovery of other, less virulent, members of the genus Ebolavirus. 44 
 45 
Ebola virus disease outbreaks 46 
Zaire ebolavirus (EBOV: WHO, 1978b), Sudan ebolavirus (SUDV: WHO, 1978a) and 47 
Bundibugyo ebolavirus (BDBV: MacNeil et al., 2010) (all family Filoviridae; genus Ebolavirus) 48 
have together caused 25 outbreaks of high mortality haemorrhagic fever that have been 49 
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officially recognised as such by the World Health Organization (WHO) (Table 1).  This figure 50 
is open to interpretation, as many of the outbreaks are temporally and geographically 51 
clustered, and some clusters may represent recurrent flare-ups of outbreaks with a single 52 
origin.  Until the Ebola-Makona strain (Kuhn et al., 2014) outbreak beginning in Guinea in 53 
late 2013, collection of virus genome data was relatively sporadic, so data is not available to 54 
answer some of the questions that Table 1 might beg.  The repeated minor recurrences of 55 
Ebola virus disease (EVD) after the end of the main wave of the west African outbreak (e.g. 56 
Blackley et al., 2016; Diallo et al., 2016), which we know from genome data to have all been 57 
Ebola-Makona in origin, might in the past have been classified as a cluster of separate 58 
outbreaks.  Therefore, 25 outbreaks since 1976 must be seen as a ceiling rather than a 59 
precise value. 60 
These EVD outbreaks have ranged in size from single cases to the 11,310 official fatalities 61 
associated with EBOV-Makona in west Africa between December 2013 and April 2016.  An 62 
additional two species in the genus, Reston ebolavirus (RESTV: Geisbert et al., 1992) and Taï 63 
Forest ebolavirus (TAFV: Le Guenno et al., 1995) have not been associated with transmission 64 
between humans, although TAFV has produced one non-fatal clinical case.  Based on the 65 
distribution of EVD outbreaks by species before 2013, it is possible to define a geographical 66 
range for each virus: EBOV in the Congo Basin and westward to the Atlantic Ocean, SUDV in 67 
Uganda and northwards into what is now South Sudan, and BDBV in an intermediate zone 68 
between the two (Figure 1).  The appearance of EBOV-Makona in eastern Guinea in 69 
December 2013 presented an additional geographical locus which disturbed the pre-2013 70 
view of EVD as a disease limited to central Africa.  The location of RESTV in Asia and TAFV in 71 
Ivory Coast did not previously affect this picture as neither had been responsible for human-72 
to-human EVD transmission.  Defining the true geographical extent of EVD is of great 73 
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importance, since the absence of west Africa from the previously accepted account of EVD 74 
incidence was a factor in the failure to recognise the disease until the outbreak was already 75 
spreading widely (Moon et al., 2015).   76 
 77 
Methods Employed in Ebola Serology  78 
Since the first recorded EVD outbreak, caused by strain EBOV-Mayinga in Yambuku, DRC 79 
(then Zaire) in 1976 (WHO, 1978b), sporadic efforts have been made to assess seropositivity 80 
in human and animal populations across Africa and occasionally elsewhere.  A variety of 81 
techniques, sample sizes and study designs have been used, together defining a larger area 82 
of tropical Africa where ebolaviruses have left their serological traces (Figure 1 and Table 2).   83 
Table 2 shows that of the 30 studies we were able to identify in the literature, 24 consisted 84 
of samples collected before 1990. Two studies (Becker et al., 1992; Tignor et al., 1993) used 85 
archive samples stored for up to two decades.  All pre-1992 studies, with one exception 86 
(Boiro et al., 1987), used immunofluorescence (IF).  Subsequent studies have all used 87 
enzyme-linked immunosorbent assay (ELISA).  Both of these techniques rely on cross-88 
reaction of serum samples with an antigen immobilised on a slide or in a well.  The antigens 89 
used for this purpose have also been highly variable, some papers specifying the strain as 90 
well as the species (e.g. Gonzalez et al., 1989; Meunier et al., 1987; Nakounne et al., 2000; 91 
Tignor et al., 1993; Van der Waals et al., 1986), with others merely the species (e.g. 92 
Blackburn et al., 1982; Mathiot et al., 1989; Rodhain et al., 1989), and a third category with 93 
even fewer details (e.g. Paix et al., 1988; Saluzzo et al., 1980).  Many of the studies were 94 
also performed in the field, often in remote areas and presumably with limited facilities for 95 
preventing degradation of both serum samples and laboratory materials.  All studies 96 
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focussed on immunological reactivity, and neutralization of virus was not studied.  Under 97 
such circumstances, scepticism concerning results is justified, and a further examination of 98 
techniques is warranted. 99 
 100 
Immunofluorescence 101 
The early IF-based methods are described in detail by Johnson et al. (1981b).  Virus-infected 102 
Vero cells in suspension were ultraviolet-irradiated to inactivate viral infectivity and then 103 
dried onto Teflon-coated microscope slides which were fixed in acetone, then gamma-104 
irradiated to destroy any residual infectivity and further sterilise both the slides and the 105 
inside of the slide box.  The infection and dilution process was titrated such that an average 106 
of less than 10% of cells per slide were infected, thus providing an internal negative control.  107 
Test samples reacting to all the surface of the slide could therefore be discarded as false 108 
positives and only those slides displaying the predicted fluorescence from 5% to 15% of cells 109 
would be scored as positive reactions.  Negative control sera were also used to differentiate 110 
slides producing non-specific reactions and antisera raised against the virus in the laboratory 111 
were used as positive controls.  In the laboratory setting, Johnson et al. (1981b) stored their 112 
IF slides at -70oC prior to use, which would be impossible in a field setting. 113 
It must be assumed that most of the early IF studies carried out in the field, used slides 114 
prepared similarly to those of Johnson et al. (1981b).  Van der Waals et al. (1986) describe 115 
some of the associated limitations.  Surveying in Liberia in 1981-1982 (Table 2), they 116 
emphasise the necessity for pre-incubation of serum with uninfected cells, as well as 117 
positive and negative controls and blind scoring.  However, having implemented this 118 
procedure for reducing false positives, they were able to differentially score EBOV-Mayinga 119 
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against SUDV-Boniface (11.8% seropositivity versus 1.6% respectively) and both against 120 
other viruses (Lassa fever 1.3%, Rift Valley fever 0.4%, Congo-Crimean haemorrhagic fever 121 
4.4% and Marburg virus 1.3%).  This capacity, shown in several of the early IF surveys, to 122 
differentially score for, and therefore by implication differentially detect, Ebolavirus species, 123 
provides a plausible internal control for the method.  For instance, Ivanoff et al. (1982) 124 
found 6% seropositivity to EBOV in their Gabonese samples but “little or no” seropositivity 125 
to SUDV and none to Marburg or Lassa viruses.  Likewise, Mathiot et al. (1989) produced a 126 
similar result – 4% to 13% seropositivity to EBOV versus zero to SUDV in Madagascar.   127 
Providing the IF slides satisfied the required controls before leaving the laboratory, and the 128 
field surveyors applied positive and negative serum controls in parallel with patient samples, 129 
while discarding samples which produced non-specific fluorescence across all cells on the 130 
slide, there is no a priori reason to reject completely the findings of the early studies.  131 
Reservations must remain about preservation of slides and control sera outside the 132 
laboratory in potentially hot climates.   133 
 134 
Enzyme-Linked Immunosorbent Assay 135 
From the early 1990s, IF methods fell into disuse in Ebola serology and were replaced with 136 
ELISA.  Boiro et al. (1987) were the first to implement ELISA in this context.  Only brief 137 
details are given in their paper, but “l’antigène du virus Ebola” without species or strain 138 
specification was bound to polystyrene microplates and incubated with guinea pig IgG to 139 
decrease non-specific binding prior to the addition of the study samples.  The secondary 140 
antibody was peroxidase-conjugated.  IF was also performed, and the antigen in that case 141 
specified as EBOV.  Unlike the earlier IF studies, many of which were performed in the field, 142 
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Boiro et al. (1987) carried out their work in the laboratory where their ELISA results could be 143 
analysed spectrophotometrically, and the reduction of the number of Ebola serology studies 144 
since the 1990s has probably partly been a consequence of this necessary additional 145 
technical requirement.  Boiro et al. (1987) also present their results very briefly, simply 146 
recording that four serum samples judged positive by ELISA also tested positive using IF, out 147 
of a total of 138 ELISA-tested and 79 IF-tested samples, within which there were 11 (8.0%) 148 
and 15 (19%) positives respectively.  The difference in positivity between methods is not 149 
relevant since the IF tests were done on convalescent patients only whereas the clinical 150 
status of the ELISA test subjects is not specified.  It is also not clear, apart from the four 151 
specifically cross-checked samples, if there is any overlap between the two sets.   152 
No other comparative study of IF against ELISA for Ebola on the same field sample set has 153 
been recorded in the literature.  Subsequent studies using ELISA have dealt with the 154 
problem of false positives by the use of positive and negative control sera, and in some 155 
cases sending the samples to other centres for independent cross-checking (Gonzalez et al., 156 
2000) or titrating the threshold for scoring positivity by reference to a sample of unexposed 157 
individuals from the USA (Boisen et al., 2015) or France (Nkoghe et al., 2011).  Heterologous 158 
incubation - e.g. when testing for EBOV, add Marburg-positive serum to remove Marburg-159 
specific binding, and vice versa – has also been used (Becker et al., 1992). 160 
 161 
Laboratory Evidence for Inter-specific Cross-reactivity 162 
Although both IF and ELISA in the field show some evidence of specificity between different 163 
viruses within the genus Ebolavirus, several laboratory studies have indicated that some 164 
cross-reactivity is likely.  A comparative study of ELISA methods using antigens prepared 165 
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from all species of the genus Ebolavirus (Macneil et al., 2011), showed cross-reactivity to be 166 
considerable, but another study considered it to be more limited (Nakayama et al., 2010).  167 
In a clinical context, sera from survivors of outbreaks displayed cross-reactivity to 168 
recombinant proteins from other filovirus species, which had been bound to a protein 169 
microarray (Natesan et al., 2016) and monoclonal antibodies raised against the 170 
glycoproteins of BDBV, SUDV and EBOV exhibit some cross-specific in vitro binding.  In the 171 
case of the anti-BDBV-GP (glycoprotein) antibodies, they were also protective against EBOV 172 
infection in guinea pigs (Flyak et al., 2016). Conversely heterologous vaccines expressing 173 
recombinant EBOV and SUDV glycoprotein are protective against infection with BDBV in 174 
macaques (Hensley et al., 2010), and viral-like particles (VLPs) have also been used to 175 
generate some cross-specific protection (Warfield et al., 2015).  Convalescent sera from the 176 
EBOV-Makona outbreak contain antibodies which cross-react with commercial EBOV and 177 
SUDV nucleoprotein antigens on Western Blot (WHO, 2015), and conversely sera from SUDV 178 
patients reacts against EBOV antigens (Sobarzo et al., 2015).  The structural basis of cross-179 
reactivity between an anti-EBOV antibody and a Marburg virus antigen has also been 180 
elucidated (Hashiguchi et al., 2015). 181 
 182 
Unexpected Results from Ebola Serology Studies 183 
Despite the technical and descriptive issues delineated above, and subsequent in vitro 184 
findings regarding cross-reactivity, Boiro et al. (1987) has become in retrospect a significant 185 
paper, in that it presents, along with the IF paper of Van der Waals et al. (1986), evidence 186 
for the occurrence of EVD in two of the three countries later affected by the 2013-2016 187 
Ebola-Makona outbreak.  If the conclusions of these two papers had been more widely 188 
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known, it might have served to alert health authorities earlier to the potential cause of the 189 
outbreak and avoid the delay that Moon et al. (2015) identify as one of the main factors in 190 
the loss of control in the early stages of the epidemic.  After the commencement of the 191 
Ebola-Makona outbreak, Schoepp et al. (2014) tested samples collected in the affected area 192 
from 2006 to 2008, using IgG and IgM-capture ELISA methods.  The IgM capture method 193 
coats the assay plates with anti-human IgM antibody rather than viral antigen.  The serum 194 
samples are then added to allow the anti-IgM antibody to bind the IgM in the samples, after 195 
which the antigen is added.  Pre-selecting in this way for the IgM within the study sample 196 
helps to reduce the potential for non-specific binding of viral antigen.  The 8.2% 197 
seropositivity rate for EBOV corresponds well to the 8.0% detected by Boiro et al. (1987), 198 
suggesting that the original paper is believable.  Boisen et al. (2015), using the same clinical 199 
source as Schoepp et al. (2014) – the Kenema General Hospital in Sierra Leone - found a 200 
higher figure of 22% including samples taken up to March 2014, just prior to the arrival of 201 
the EBOV-Makona strain in Kenema. 202 
One of the most surprising results in Ebola serology comes from a study performed in 203 
Germany (Becker et al., 1992) on an anonymised heterogeneous sample set collected over a 204 
19 year period from 1972 to 1991, comprising contacts of the original Marburg virus 205 
outbreak patients, routine diagnostic samples from Marburg (western-central Germany), 206 
blood donors and others of unspecified origin and a sample set from Greifswald (on the 207 
Baltic coast of north-east Germany).  This is the only study to combine ELISA, IF and Western 208 
blot methods.  ELISA was carried out in the first instance, and then the positive samples 209 
cross-checked with IF and Western blotting with confirmation rates in excess of 66% for all 210 
antigens tested.  The initial ELISAs used heterologous incubation to address the problem of 211 
cross-specificity.  REBOV has the highest positivity at 3.4% followed by Marburg at 2.6% and 212 
 10 
EBOV at 0.85%.  The study provides no information about the travel history or birthplace of 213 
individuals, which means that the possibility that the signal represents travel-related 214 
exposure, rather than autochthonous transmission within Europe, cannot be discounted.   215 
 216 
Candidate Reservoir Serology in Africa 217 
Three fruit bat species (Hypsignathus monstrosus, Epomops franqueti, and Myonycteris 218 
torquata) have been hypothesised to be the natural reservoir host of EBOV on the basis of 219 
detection of viral genomes (Leroy et al., 2005), but the human seropositive zone is wider 220 
than their incidence (Figure 1), suggesting that our current knowledge of the animal 221 
reservoir is incomplete.  Other species of fruit bat with a wider range may be involved, and a 222 
serological study of Eidolon helvum in Zambia between 2006 and 2013 showed annual 223 
seropositivity fluctuating between zero and 6% for any one filovirus, with all species tested 224 
(EBOV, SUDV, REBOV, BDBV, TAFV and Marburg virus) occurring at least once over the study 225 
period, but different species dominating in different years, and EBOV and SUDV being jointly 226 
the most common (Ogawa et al., 2015).  Several bat species in Ghana (Hayman et al., 2010; 227 
2012) and Gabon (Pourrut et al., 2007; 2009) were also shown to be seropositive.  Outside 228 
of Africa, seropositive bats have been detected in Bangladesh (Olival et al., 2013) and China 229 
(Yuan et al., 2012). 230 
Of course, serological studies in bats share all the interpretational problems of those in 231 
humans.  Not all studies have been positive – the first extensive investigation (Leirs et al., 232 
1999) into seropositivity in African mammals, using ELISA, conducted following the 1995 233 
EBOV outbreak in Kikwit, Zaire (Table 1) sampled 3066 specimens drawn from 2493 species 234 
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and failed to find any seropositivity including in the fruit bat Epomops franqueti from which a 235 
later study isolated a fragment of viral genome (Leroy et al., 2005) 236 
It is known that apes are susceptible to EVD (Walsh et al., 2003) and also have signals of 237 
seropositivity (Becker et al., 1992; Johnson et al., 1981a; 1982; Leroy et al., 2004a; 2004b; 238 
Nidom et al., 2012; Rouquet et al., 2005) but their status seems to be more similar to that of 239 
humans as occasional victims of epidemics, rather than to represent a reservoir population.  240 
Likewise, surveys of other mammals have shown seropositivity in domestic animals (Allela et 241 
al., 2005; Stansfield et al., 1982) and limited evidence of virus genomes (Morvan et al., 242 
1999) or disease (Leroy et al., 2004a; Rouquet et al., 2005) in small mammals. 243 
 244 
Human Serological and Clinical Ranges in Africa 245 
However, if the serological signal in humans represents the true geographical range of the 246 
genus Ebolavirus, this begs the question as to why EVD outbreaks were not more widely 247 
distributed prior to 2013.  The serological signal is consistent over time; some African 248 
countries having been sampled extensively in terms of number of studies, geographical 249 
range and variety of different reporting research groups.  The Central African Republic (CAR) 250 
has been the subject of seven published studies, carried out between 1979 and 1997 (Figure 251 
1; Table 2).  Several sites have been sampled more than once, with maximum seropositivity 252 
at 23%, despite no recorded EVD outbreak having occurred in the CAR.  Prior to the first EVD 253 
outbreak in Gabon in 1994, that country was the subject of a sero-surveys in 1980 and 1985-254 
1987 indicating a maximum seropositivity of 22% (Table 2) and identifying seropositive 255 
subjects in some of the areas where EVD subsequently broke out in 1994-1996 and 2001-256 
2002 (Figure 1).  All three countries involved in the 2013-2016 EBOV-Makona outbreak had 257 
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given positive signals over four studies from 1981 to 2011, three of which involved patients 258 
with haemorrhagic fevers of unknown aetiology (Table 2).  259 
We therefore next discuss three scenarios that could account for the discrepancy between 260 
EVD’s range when defined clinically versus serologically, and their implications both for our 261 
understanding of the biology of the genus Ebolavirus and future risk assessment. 262 
 263 
Hypothesis 1: EVD outbreaks have been misidentified as other diseases in the 264 
past 265 
Although the international response to the EBOV-Makona outbreak was criticised on several 266 
counts (Moon et al., 2015), there was much media interest from the beginning.  A similar 267 
level of media interest was stimulated in 1995 by the EBOV-Kikwit outbreak (Garrett, 2001), 268 
and recognition of the potential seriousness of EVD outbreaks and consequent surveillance 269 
began almost as soon as EBOV and SUDV were discovered in the late 1970s (Table 3).  Under 270 
these circumstances, it perhaps seems unlikely that an EVD outbreak could have passed 271 
completely unnoticed.   272 
However, this would presumably not apply to outbreaks occurring before the discovery of 273 
EBOV in 1976.  One potential event in that category was the 1961-1962 outbreak in Ethiopia 274 
of a disease described at the time as yellow fever (Tignor et al., 1993).  Even after 1976, 275 
some of the population sero-surveys identified clusters of patients with fevers, for instance 276 
in Kenya (Johnson et al., 1983b; 1986) and west Africa (Boiro et al., 1987; Boisen et al., 277 
2015; Schoepp et al., 2014) which may represent small EVD outbreaks that escaped official 278 
classification, speculation being particularly focussed on Guinea in 1982-1983 (Balde, 2014; 279 
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Boiro et al., 1987).  Corroboration of this hypothesis would require work to be done by 280 
medical historians to identify previous disease outbreaks that may have been unrecognised 281 
EVD.  A similar effort was undertaken in the 1980s to identify traces in the literature of 282 
potential cases of pre-1979 HIV-1 infection in Africa, without much success.  Our knowledge 283 
of the pre-history of AIDS comes largely from retrospective serology and phylogenetic 284 
reconstruction, and this may also remain the case for EVD. 285 
 286 
Hypothesis 2: The genus Ebolavirus is larger than currently known, and 287 
includes milder species with a wider geographical range 288 
The finding of seropositive individuals does not necessarily indicate that those individuals 289 
have been exposed to EBOV, BDBV or SUDV.  As reviewed above, reports of cross-specificity 290 
in vitro make it likely that some of the serological tests detect other members of the genus 291 
Ebolavirus or related filoviruses.  Human population serology may simply indicate the 292 
geographical range of the genus or the family as a whole.  The discovery of TAFV in 1994, 293 
still limited to a single case in humans, illustrates that very rare Ebolavirus species do exist, 294 
so it is plausible that more species diversity remains to be discovered.  These hypothetical 295 
extra members of the genus Ebolavirus would presumably be relatively mild compared to 296 
EBOV, BDBV and SUDV, and thus have not produced any recognised outbreaks of EVD.  TAFV 297 
produced a “dengue-like syndrome” in its single human case (Le Guenno et al., 1995). 298 
 299 
Hypothesis 3: EVD may be subclinical with a frequency high enough that 300 
smaller outbreaks may be unidentified  301 
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Post-outbreak sero-surveys (Table 3) conducted in the wake of prior EVD events (Table 1) 302 
have often shown localised high levels of seropositivity.  Some settlements in the vicinity of 303 
the second Zaire outbreak of 1977 had seropositivity at 56% (Van der Groen & Pattyn, 1979) 304 
and 32% was recorded in parts of Gabon exposed to the 2001-2002 outbreak (Nkoghe et al., 305 
2011).  These numbers would appear to be too large to be simply representative of known 306 
patients, and suggest a larger body of affected individuals, some of whom possibly might 307 
have been sub-clinical.  However, Jezek et al. (1999), returning in the early 1980s to the 308 
scene of the 1976 and 1977 EBOV outbreaks in Zaire, detected 60% seropositivity in 309 
recovered patients, but only 1% in the general population, suggesting that the bulk of 310 
seropositivity is due to those who have had a recognised previous EVD attack.  On the other 311 
hand, these same authors also scored asymptomatic contacts at 18% seropositive.  Other 312 
studies on asymptomatic contacts of known cases have given seropositivity scores as high as 313 
32% for the 1979 SUDV outbreak (Baron et al., 1983) and 50% for the 1996 Gabon EBOV 314 
outbreak (Leroy et al., 2000).  In the latter study, viral RNA was also isolated from 7 out of 315 
the 11 seropositive asymptomatic contacts, but from none of 13 seronegative contacts.  A 316 
meta-analysis by Dean et al. (2016) covering many of the studies in Tables 2 and 3, 317 
estimated that 14-40% of EBOV infections are asymptomatic. 318 
However, these studies do not conclusively prove that the asymptomatic contacts 319 
contracted sub-clinical EVD, despite the circumstantial implication.  Becquart et al. (2014) 320 
compared sera from asymptomatic seropositive individuals with equivalent samples from 321 
symptomatic survivors showing that IgG responses were qualitatively different in each 322 
group.  The asymptomatic group displayed greater response to EBOV VP40 (40 kDa protein), 323 
whereas the survivors known to have been infected with EBOV had their greatest IgG 324 
response to GP.  This might be consistent with the seropositive individuals within the 325 
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asymptomatic group having been previously infected with a non-EBOV filovirus, perhaps 326 
one with greater sequence/antigenic similarity to EBOV in its VP40 than its GP.  327 
Alternatively, it might indicate some variation in the immune response that contributes to 328 
the asymptomatic state. 329 
The EBOV-Makona outbreak of 2013-2016 produced 28,616 official confirmed or suspected 330 
cases, allowing a far more extensive investigation of seropositivity in a human population 331 
than had previously been possible.  Asymptomatic relatives of Ebola-Makona victims were 332 
routinely identified as seropositive, as high as 65% for the later stages of the outbreak in 333 
Sierra Leone (de La Vega et al., 2015).  Of course, it must be noted that the stigma 334 
associated with EVD, recognised in both the EBOV 1995 and SUDV 2000 outbreaks 335 
(Kinsman, 2012) and emerging as a major factor in the EBOV-Makona outbreak 336 
(Karamouzian & Hategekimana, 2015), may have led to a reluctance among the contacts of 337 
EVD cases to admit their own symptoms.  Those subsequently classified as asymptomatic 338 
contacts may therefore have been true survivors.  Gignoux et al. (2015) used a statistical 339 
comparison of two databases of patients covering Montserrado, Liberia from June to August 340 
2014 to estimate that the true number of clinical EVD cases was 3-fold higher than the 341 
reported number.  It is unclear however if this is due to administrative deficiencies or 342 
deliberate under-reporting. 343 
 344 
Conclusions and Future Prospects 345 
The serological footprint of Ebola is wider than expected from our knowledge of EVD 346 
outbreaks.  Each sero-survey must be considered on its own merits, as a variety of methods 347 
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have been used over the years, with differing degrees of technical sophistication and 348 
attention to controls for false positives.  Nevertheless, the most recent experiments remain 349 
generally supportive of the idea that contact between humans and some viruses of the 350 
genus Ebolavirus, although not necessarily any of the known ones, has occurred in tropical 351 
Africa outside of known outbreak zones.  Caution must be exercised before making similar 352 
statements concerning Europe and Asia.  The former has no recent study and seropositive 353 
signals in the latter may be accounted for by RESTV. 354 
Each of the three scenarios listed here can draw on some support from the data.  355 
Hypothesis 3 - a widespread occurrence of asymptomatic EBOV infections - would perhaps 356 
be the most troubling, as this would imply that EBOV is far more common than previously 357 
appreciated, and across a wide area of Africa, presenting the possibility that full-blown EVD 358 
crises may arise at any time.  It does, however, beg the question of why some EBOV 359 
outbreaks would consist largely of asymptomatic cases, in contrast to a more typical 360 
devastating EVD episode.  Nevertheless, wherever efforts have been made to assess 361 
exposure to the virus among asymptomatic contacts, most studies have figures in excess of 362 
18% (Table 3). 363 
Hypothesis 1 - more clinically conventional, but nevertheless missed, EVD outbreaks - may 364 
therefore require fewer assumptions.  However, it requires us to explain why our postulated 365 
extra EVD outbreaks have not been detected, especially after 1976 when surveillance for 366 
haemorrhagic fevers intensified.  There may be evidence in the colonial medical literature of 367 
outbreaks that were classified according to the diseases known at the time, but which now 368 
in retrospect may seem more probably to be EVD outbreaks.  However, the serological 369 
traces in modern human populations of such outbreaks would be confined to the very 370 
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elderly, and we need to account for unexplained Ebola seropositivity in younger individuals 371 
too. 372 
A compromise between hypotheses 1 and 3 may be possible, if EVD outbreaks are normally 373 
very small and localised with a high proportion of asymptomatic cases.  The documented 374 
EVD outbreaks since 1976 would then represent the extreme end of a probability 375 
distribution, being only those outbreaks large enough to present sufficient fatal cases to 376 
attract attention.  This however, would require an answer as to why known EVD outbreaks, 377 
until 2013, were all in a relatively restricted region of central Africa comprising the Congo 378 
Basin and areas to its east and west, whereas the Ebola seropositivity signal is far wider. 379 
Hypothesis 2 - the existence of other members of the genus Ebolavirus - may therefore be 380 
the least problematic answer, as it does not require any revision of our understanding of 381 
EVD as caused by three virulent, and until 2013 solely central African, species in that genus.  382 
The relatively little that we know concerning RESTV and TAFV is consistent with the idea of 383 
reduced pathogenicity in humans of some species of Ebolavirus.  Where cross-reactivity 384 
experiments have been performed, there appears to be an indication that exposure to one 385 
member of the genus Ebolavirus can produce antibodies that will bind other members to a 386 
greater (Flyak et al., 2016; Hashiguchi et al., 2015; Hensley et al., 2010; Macneil et al., 2011; 387 
Natesan et al., 2016; WHO, 2015) or lesser (Nakayama et al., 2010) degree.   388 
There is therefore considerable justification for a renewal of the Ebola sero-survey research 389 
programme, which has atrophied since the 1990s.  This should be coupled with a deep 390 
sequencing initiative in candidate reservoir hosts, especially bats.  Discovery of new 391 
members of the genus Ebolavirus could account for the widespread seropositivity among 392 
humans.  Since even current standard immunological tests based on antigen-antibody 393 
 18 
binding cannot distinguish different species of Ebolavirus with absolute reliability, 394 
methodological research is required to make the next generation of serology techniques as 395 
precise as those currently based on genome sequencing.  The same concerns apply to other 396 
viral genera, for instance Flavivirus, where Zika and dengue exhibit cross-reactivity 397 
(Dejnirattisai et al., 2016; Priyamvada et al., 2016).  Conclusions about Zika’s clinical 398 
occurrence prior to the beginning of the large Pacific/Americas outbreak are therefore both 399 
crucial to assessment of the degree of herd immunity to Zika and based on potentially 400 
unreliable data. 401 
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  717 
Figure Legend 718 
 719 
Figure 1:  Locations of EVD outbreaks and of seropositive human populations prior to 720 
known outbreaks.  Black square: EBOV outbreak; ochre square: BDBV outbreak; purple 721 
 25 
square: SUDV outbreak; blue square: TAFV case; red circle: seropositive result in a 722 
population survey prior to outbreak in that area; dotted line: range of three fruit bat species 723 
implicated as EBOV reservoirs.  Squares mark epicentres of outbreaks, total range was often 724 
larger.  Seropositive populations sampled after EVD outbreaks in same region are not shown 725 




Year  Country  Species  Cases  Deaths  CFR 
2013-2016 
Guinea, Liberia, Sierra 
Leone EBOV 28,616 11,310 40% 
2014 DRC (Zaire) EBOV 66 49 74% 
2012 DRC (Zaire) BDBV  57 29 51% 
2012 Uganda  SUDV  7 4 57% 
2012 Uganda  SUDV  24 17 71% 
2011 Uganda  SUDV  1 1 100% 
2008 DRC (Zaire) EBOV  32 14 44% 
2007 Uganda  BDBV  149 37 25% 
2007 DRC (Zaire) EBOV  264 187 71% 
2005 Congo  EBOV  12 10 83% 
2004 Sudan  SUDV  17 7 41% 
2003  Congo  EBOV  35 29 83% 
2003  Congo  EBOV  143 128 90% 
2001-2002  Congo  EBOV  59 44 75% 
2001-2002  Gabon  EBOV  65 53 82% 
2000 Uganda  SUDV  425 224 53% 
1996 South Africa (ex-Gabon)  EBOV  1 1 100% 
1996  Gabon  EBOV  60 45 75% 
1996  Gabon  EBOV  31 21 68% 
1995 Zaire EBOV  315 254 81% 
1994 Gabon  EBOV  52 31 60% 
1979 Sudan  SUDV  34 22 65% 
1977 Zaire EBOV  1 1 100% 
1976 Sudan  SUDV  284 151 53% 
1976 Zaire EBOV 318 280 88% 
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Table 1:  The 25 officially declared outbreaks of EVD from 1976 to 2016.  CFR: case fatality 731 
rate. EBOV: Zaire ebolavirus; SUDV: Sudan ebolavirus; BDBV: Bundibugyo ebolavirus. Data 732 
from WHO (2016) 733 
 734 
Sampling 
date Region Method % seropositive Reference 
1961-1962 8 locations, Ethiopia IF – Mayinga  7-39 Tignor et al. (1993) 
1972-1991 Germany ELISA/IF/WB* Filovirus 7, EBOV 1 Becker et al. (1992) 
1979 Bangassou, CAR IF 3 Saluzzo et al. (1980) 
1980 Franceville, Gabon IF – EBOV  6 Ivanoff et al. (1982) 
1980 5 locations, Cameroon IF 3-14 
Bouree and Bergmann 
(1983) 
1980 4 locations, Zimbabwe IF – EBOV  1-3 Blackburn et al. (1982) 
1980-1981 Nzoia, Kenya IF – EBOV  1 (patients) Johnson et al. (1983b) 
1981-1982 Grand Bassa, Liberia IF – Mayinga/Boniface EBOV 12, SUDV 2 Van der Waals et al. (1986) 
1982-1983 Madina-Oula, Guinea ELISA/IF – EBOV 19 (patients), 8 Boiro et al. (1987) 
pre-1983 6 locations, Kenya IF – Mayinga/SUDV EBOV 1-7, SUDV <1 Johnson et al. (1983a) 
1983 Awash Valley, Ethiopia IF – Mayinga  30 Tignor et al. (1993) 
1984 4 locations, Uganda IF – EBOV/SUDV EBOV 3, SUDV 3 Rodhain et al. (1989) 
1984-1985 13 locations, CAR IF - filovirus† Filovirus 4-23 Meunier et al. (1987) 
1984-1985 Kenya IF – EBOV/SUDV  10 (patients) Johnson et al. (1986) 
1985 Nkongsamba, Cameroon IF 2 Paix et al. (1988) 
1985-1987 N'Djamena, Chad IF – Mayinga/Boniface 4 Gonzalez et al. (1989) 
1985-1987 3 locations, Cameroon IF – Mayinga/Boniface 2-11 Gonzalez et al. (1989) 
1985-1987 Bangui, CAR IF – Mayinga/Boniface 33 Gonzalez et al. (1989) 
1985-1987 
Bioco/Nsork, Equatorial 
Guinea IF – Mayinga/Boniface 16 Gonzalez et al. (1989) 
1985-1987 5 locations, Gabon IF – Mayinga/Boniface 7-22 Gonzalez et al. (1989) 
1985-1987 2 locations, Congo IF – Mayinga/Boniface 6-8 Gonzalez et al. (1989) 
pre-1987 Benue-Gongola, Nigeria IF – EBOV/SUDV 2 Tomori et al. (1988) 
1987 Mongoumba, CAR IF – EBOV/SUDV 18 Johnson et al. (1993a) 
pre-1988 Madagascar IF – EBOV/SUDV EBOV 4-13, SUDV 0 Mathiot et al. (1989) 
pre-1992 4 locations, CAR IF – Mayinga/Boniface 
EBOV 1-9, SUDV 19-
27 Johnson et al. (1993b) 
1992-1996 4 locations, CAR ELISA – Mayinga  4-7 Gonzalez et al. (2000) 
1992-1997 3 locations, CAR ELISA – Mayinga 2-13 Nakounne et al. (2000) 
2002 Watsa, DRC ELISA – EBOV  19 Mulangu et al. (2016)  
2006-2008 Kenema, Sierra Leone ELISA – EBOV 9 (patients) Schoepp et al. (2014) 
2011-2014 Kenema, Sierra Leone ELISA – Mayinga‡ 22 (patients) Boisen et al. (2015) 
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Table 2:  Sero-surveys with positive results conducted in regions of Africa where no EVD 736 
outbreak has occurred, or prior to the occurrence of EVD in that region. Where a variety of 737 
locations were sampled, the range of seropositivity is given. CAR: Central African Republic; 738 
DRC: Democratic Republic of Congo.  IF: immunofluorescence; ELISA: enzyme-linked 739 
immunosorbent assay; WB: Western blot.  Where EBOV and SUDV were assayed separately, 740 
corresponding values are given.  Species or strain of Ebolavirus antigen used also given 741 
when specified in publication.  “Patients” indicates that the subjects were suffering from a 742 
haemorrhagic fever at the time of the test.  Where no specific date for the survey is given in 743 
the paper, submission date of the paper is used as “pre-19nn”. *Becker et al. (1992) used 744 
Mayinga (EBOV), RESTV and Musoke (Marburgvirus).  †Meunier et al. (1987) used Mayinga, 745 









1972-1978 N.W. Zaire EBOV 1977 IF 13-56 
 




Zaire EBOV 1976 IF <1 2.5 
WHO (1978b) 
1978 Tandala area, Zaire EBOV 1977 IF 4-10 
 




Sudan SUDV 1976, 1979 IF 18 32 
Baron et al. (1983) 
1981 Tandala, Zaire EBOV 1977 IF 5 
 
Stansfield et al. 
(1982) 
1981-1985 Sud-Ubangi, Zaire EBOV 1976, 1977 IF 
60 (patients), 
<1 18 
Jezek et al. (1999) 
1986 Juba, Sudan SUDV 1976, 1979 IF 5 (patients) 
 
Woodruff et al. 
(1988) 
1995 Kikwit, Zaire EBOV 1995 ELISA 3 
 
Tomori et al. (1999) 
1995 Kikwit, Zaire EBOV 1995 ELISA 2-18 
 
Busico et al. (1999) 
1995 Bandundu, Zaire EBOV 1995   3 (Rowe et al., 1999) 
1996 N. Gabon EBOV 1996 ELISA/WB 
 
50 Leroy et al. (2000) 
1996 
Ogooue-Ivindo, 
Gabon EBOV 1996 ELISA 10 
 




Gabon EBOV 1996 ELISA 1 
 
Heffernan et al. 
(2005) 
2005-2008 Gabon EBOV 2001-2002 ELISA 3-21 
 
Becquart et al. 
 28 
(2010) 
2005-2008 Gabon EBOV 2001-2002 ELISA <1-32 
 




Leone EBOV 2013-2016 ELISA 
 
20-65 
de La Vega et al. 
(2015) 
 748 
Table 3:  Sero-surveys with positive results conducted in regions of Africa subsequent to 749 
an EVD outbreak, divided into general population seropositivity, and contacts of known 750 
cases where available. Where a variety of locations were sampled, the range of 751 
seropositivity is given.  IF: immunofluorescence; ELISA: enzyme-linked immunosorbent 752 
assay; WB: Western blot.  “Patients” indicates that the subjects were suffering from a 753 
haemorrhagic fever at the time of the test.  754 
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